Scott W. Powers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Scott W. Powers has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Andrew D. Hershey
Division of Neurology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
8 shared publications Andrew D. Hershey
Division of Neurology (AG), Le Bonheur Children's Hospital, Memphis, TN; Division of Neurology (AG, PSH, MKS, JK, SLL, SW, ADH), Cincinnati Children's Hospital; Department of Pediatrics (PSH, MKS, JK, SWP, ADH), University of Cincinnati College of Medicine; and Division of Behavioral Medicine and Clinical Psychology (SWP), Cincinnati Children's Hospital Medical Center, OH
7 shared publicationsAshley M. Kroon Van Diest
Department of Pediatric Psychology and Neuropsychology, Nationwide Children's Hospital, Columbus, OH, USA
7 shared publicationsMarielle A. Kabbouche
Cincinnati Children’s Headache Center, Cincinnati, Ohio
6 shared publicationsJanelle R. Allen
Behavioral Medicine and Clinical Psychology
5 shared publicationsLeigh A. Chamberlin
Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
5 shared publications
Latest Publications
- 1 June 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (3) , e200294
Clinic-Based Characterization of Adolescents and Young Adults With Migraine
This cross-sectional observational study retrospectively examined clinical data collected from adolescents and young adults (AYAs) seeking care in a specialty headache clinic. We characterized participants' headache characteristics and psychological functioning and examined the association between self-reported anxiety and depressive symptoms and headache frequency, severity, and disability. During their clinic visit, AYAs (M age = 18.36; range = 14-32, 79.5% female) completed an intake questionnaire and reported about their headache characteristics (i.e., frequency, severity, and duration of symptoms in months), mental health history (i.e., previous diagnosis of an anxiety or depressive disorder), and utilization of emergency department (ED) services for migraine. AYAs also completed psychometrically validated screening tools for anxiety and depressive symptoms (i.e., the GAD-7 and PHQ-9). We computed descriptive statistics and examined associations among scores on psychological measures and headache characteristics, including migraine-related disability. We also tested whether individuals with clinically elevated GAD-7 and PHQ-9 scores had higher levels of disability relative to those with fewer/subclinical levels of anxiety and depressive symptoms. Participants (N = 283) reported more than 19 headache days per month on average, with more than 90% describing their average headache intensity as moderate or severe. Nearly half of AYAs reported severe headache-related disability. Approximately one-quarter of AYAs reported a previous diagnosis anxiety or depressive disorder diagnosis, and more than one-third scored above clinical cutoffs on the PHQ-9 and GAD-7. Higher scores on both psychological screening instruments were associated with greater headache frequency. More than 10% of patients endorsed current suicidal ideation; this was not related to headache-related disability. Participants reported a high degree of ED utilization for headache; these rates were unrelated to endorsement of psychological comorbidities. In this sample of AYAs, headache characteristics were generally unrelated to scores on measures on psychological functioning. However, the observed rates of clinically elevated anxiety/depressive symptoms and suicidality in this sample of AYAs underscore the importance of screening for psychological comorbidities in neurology clinics that serve this age group, irrespective of self-reported disability. Results also emphasize the need to expand access to behavioral health services for AYAs with headache disorders and the importance of incorporating a biopsychosocial perspective to the transition of health care from pediatrics to adult neurology practice.
- 1 June 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (3) , e200294
Clinic-Based Characterization of Adolescents and Young Adults With Migraine
This cross-sectional observational study retrospectively examined clinical data collected from adolescents and young adults (AYAs) seeking care in a specialty headache clinic. We characterized participants' headache characteristics and psychological functioning and examined the association between self-reported anxiety and depressive symptoms and headache frequency, severity, and disability. During their clinic visit, AYAs (M age = 18.36; range = 14-32, 79.5% female) completed an intake questionnaire and reported about their headache characteristics (i.e., frequency, severity, and duration of symptoms in months), mental health history (i.e., previous diagnosis of an anxiety or depressive disorder), and utilization of emergency department (ED) services for migraine. AYAs also completed psychometrically validated screening tools for anxiety and depressive symptoms (i.e., the GAD-7 and PHQ-9). We computed descriptive statistics and examined associations among scores on psychological measures and headache characteristics, including migraine-related disability. We also tested whether individuals with clinically elevated GAD-7 and PHQ-9 scores had higher levels of disability relative to those with fewer/subclinical levels of anxiety and depressive symptoms. Participants (N = 283) reported more than 19 headache days per month on average, with more than 90% describing their average headache intensity as moderate or severe. Nearly half of AYAs reported severe headache-related disability. Approximately one-quarter of AYAs reported a previous diagnosis anxiety or depressive disorder diagnosis, and more than one-third scored above clinical cutoffs on the PHQ-9 and GAD-7. Higher scores on both psychological screening instruments were associated with greater headache frequency. More than 10% of patients endorsed current suicidal ideation; this was not related to headache-related disability. Participants reported a high degree of ED utilization for headache; these rates were unrelated to endorsement of psychological comorbidities. In this sample of AYAs, headache characteristics were generally unrelated to scores on measures on psychological functioning. However, the observed rates of clinically elevated anxiety/depressive symptoms and suicidality in this sample of AYAs underscore the importance of screening for psychological comorbidities in neurology clinics that serve this age group, irrespective of self-reported disability. Results also emphasize the need to expand access to behavioral health services for AYAs with headache disorders and the importance of incorporating a biopsychosocial perspective to the transition of health care from pediatrics to adult neurology practice.
- 1 October 2023
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 13 (5) , e200188
Characterization of Migraine in Children and Adolescents With Generalized Joint Hypermobility
Background and Objectives The prevalence of generalized joint hypermobility (GJH) is 5–65% in children and adolescents. The hypothesis of this study was to see whether there is an association between headache characteristics and GJH in children and adolescents with migraine. Methods We performed a primary retrospective case-control analysis of an established database of patients with headache aged 5–17 years. Results We included 5435 participants. Approximately 31.6% of participants (1,719/5,435) were diagnosed with GJH (Beighton score ≥ 6). Nausea (73.1% vs 67.5%, χ2 with 1 degree of freedom = 17.0, p < 0.0001), phonophobia (87.3% vs 78.8%, χ2 with 1 degree of freedom = 18.0, p < 0.0001), and the PedMIDAS score (48.2 ± 52.5, 95% CI 45.7–50.6 vs 41.6 ± 51.2, 95% CI 40.0–43.3, effect size = 0.13, p < 0.0001) were noted to be more severe in participants with GJH than those without GJH. Discussion Youths with GJH and migraine were noted to have more severe migraine characteristics.
- 1 October 2023
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 13 (5) , e200188
Characterization of Migraine in Children and Adolescents With Generalized Joint Hypermobility
Background and Objectives The prevalence of generalized joint hypermobility (GJH) is 5–65% in children and adolescents. The hypothesis of this study was to see whether there is an association between headache characteristics and GJH in children and adolescents with migraine. Methods We performed a primary retrospective case-control analysis of an established database of patients with headache aged 5–17 years. Results We included 5435 participants. Approximately 31.6% of participants (1,719/5,435) were diagnosed with GJH (Beighton score ≥ 6). Nausea (73.1% vs 67.5%, χ2 with 1 degree of freedom = 17.0, p < 0.0001), phonophobia (87.3% vs 78.8%, χ2 with 1 degree of freedom = 18.0, p < 0.0001), and the PedMIDAS score (48.2 ± 52.5, 95% CI 45.7–50.6 vs 41.6 ± 51.2, 95% CI 40.0–43.3, effect size = 0.13, p < 0.0001) were noted to be more severe in participants with GJH than those without GJH. Discussion Youths with GJH and migraine were noted to have more severe migraine characteristics.
- Open Access
- 15 May 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (5)
Issue Information
- 15 May 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (5)
Open AccessIssue Information
- 9 February 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (6) , 805-812
Impact of preventive pill‐based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention ( CHAMP ) trial and a comparison of self‐report to nosology‐derived assessments
Objective: To examine group differences in self‐reported migraine days among youth who completed the Childhood and Adolescent Migraine Prevention (CHAMP) trial prior to its closure and explore the relationship between self‐reported and “nosology‐derived” (i.e., International Classification of Headache Disorders, 3rd edition [ICHD‐3]) migraine days. Background: The CHAMP trial compared amitriptyline and topiramate to placebo for migraine prevention in youth and proposed to analyze change in migraine days as a secondary outcome. There is considerable variability in the field regarding what constitutes a “migraine day,” how this is determined and reported in trials, and how consistent these measures are with diagnostic nosology. Methods: CHAMP trial completers ( N = 175) were randomized to receive amitriptyline ( n = 77), topiramate ( n = 63), or placebo ( n = 35). Participants maintained daily headache diaries where they reported each day with headache and if they considered that headache to be a migraine. For each headache day, participants completed a symptom record and reported about symptoms such as pain location(s) and presence of nausea/vomiting or photophobia and phonophobia. We examined group differences in self‐reported migraine days at trial completion (summed from trial weeks 20–24) compared to baseline. We also used an algorithm to determine whether participants’ symptom reports met ICHD‐3 criteria for migraine without aura, and examined the association between self‐reported and “nosology‐derived” migraine days. Results: Results showed no significant differences between groups in self‐reported migraine days over the course of the trial. Self‐reported and “nosology‐derived” migraine days during the baseline and treatment phases were strongly associated ( r 's = 0.73 and 0.83, respectively; p 's < 0.001). Conclusion: Regardless of treatment, CHAMP trial completers showed clinically important reductions in self‐reported migraine days over the course of the trial (about 3.8 days less). The strong association between self‐reported and “nosology‐derived” migraine days suggests youth with migraine can recognize a day with migraine and reliably report their headache features and symptoms. Greater rigor and transparency in the calculation and reporting of migraine days in trials is needed.
- 9 February 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (6) , 805-812
Impact of preventive pill‐based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention ( CHAMP ) trial and a comparison of self‐report to nosology‐derived assessments
Objective: To examine group differences in self‐reported migraine days among youth who completed the Childhood and Adolescent Migraine Prevention (CHAMP) trial prior to its closure and explore the relationship between self‐reported and “nosology‐derived” (i.e., International Classification of Headache Disorders, 3rd edition [ICHD‐3]) migraine days. Background: The CHAMP trial compared amitriptyline and topiramate to placebo for migraine prevention in youth and proposed to analyze change in migraine days as a secondary outcome. There is considerable variability in the field regarding what constitutes a “migraine day,” how this is determined and reported in trials, and how consistent these measures are with diagnostic nosology. Methods: CHAMP trial completers ( N = 175) were randomized to receive amitriptyline ( n = 77), topiramate ( n = 63), or placebo ( n = 35). Participants maintained daily headache diaries where they reported each day with headache and if they considered that headache to be a migraine. For each headache day, participants completed a symptom record and reported about symptoms such as pain location(s) and presence of nausea/vomiting or photophobia and phonophobia. We examined group differences in self‐reported migraine days at trial completion (summed from trial weeks 20–24) compared to baseline. We also used an algorithm to determine whether participants’ symptom reports met ICHD‐3 criteria for migraine without aura, and examined the association between self‐reported and “nosology‐derived” migraine days. Results: Results showed no significant differences between groups in self‐reported migraine days over the course of the trial. Self‐reported and “nosology‐derived” migraine days during the baseline and treatment phases were strongly associated ( r 's = 0.73 and 0.83, respectively; p 's < 0.001). Conclusion: Regardless of treatment, CHAMP trial completers showed clinically important reductions in self‐reported migraine days over the course of the trial (about 3.8 days less). The strong association between self‐reported and “nosology‐derived” migraine days suggests youth with migraine can recognize a day with migraine and reliably report their headache features and symptoms. Greater rigor and transparency in the calculation and reporting of migraine days in trials is needed.
- 1 January 2022
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 26 (1) , 85-91
Psychological Interventions for Pediatric Headache Disorders: A 2021 Update on Research Progress and Needs
Purpose of Review This review summarizes key findings from recent investigations of psychological interventions for pediatric headache disorders and discusses important avenues for future research. Recent Findings Cognitive Behavioral Therapy (CBT) is effective in reducing headache days among youth with chronic headache. There is mixed evidence for the benefit of CBT on reducing disability associated with migraine, suggesting that there is room to optimize CBT by leveraging complementary or alternative psychological interventions, such as Acceptance and Commitment Therapy (ACT) and mindfulness-based approaches. Tailoring CBT may be especially important for youth with more impairing or complex clinical presentations, such as those with continuous headache. Using eHealth and novel study designs to expand access to and dissemination of psychological interventions is promising. Summary Although CBT is the gold standard psychological treatment for youth with migraine, we are only beginning to understand how and why it is effective. Other promising psychological treatments are available, and studies are beginning to examine how CBT can be optimized to fit the unique needs of each patient. Improving access and equitability of care for youth with migraine will require tailoring psychological treatments for patients with varying headache presentations and youth from a variety of cultural, racial, ethnic, and linguistic backgrounds.
- 1 January 2022
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 26 (1) , 85-91
Psychological Interventions for Pediatric Headache Disorders: A 2021 Update on Research Progress and Needs
Purpose of Review This review summarizes key findings from recent investigations of psychological interventions for pediatric headache disorders and discusses important avenues for future research. Recent Findings Cognitive Behavioral Therapy (CBT) is effective in reducing headache days among youth with chronic headache. There is mixed evidence for the benefit of CBT on reducing disability associated with migraine, suggesting that there is room to optimize CBT by leveraging complementary or alternative psychological interventions, such as Acceptance and Commitment Therapy (ACT) and mindfulness-based approaches. Tailoring CBT may be especially important for youth with more impairing or complex clinical presentations, such as those with continuous headache. Using eHealth and novel study designs to expand access to and dissemination of psychological interventions is promising. Summary Although CBT is the gold standard psychological treatment for youth with migraine, we are only beginning to understand how and why it is effective. Other promising psychological treatments are available, and studies are beginning to examine how CBT can be optimized to fit the unique needs of each patient. Improving access and equitability of care for youth with migraine will require tailoring psychological treatments for patients with varying headache presentations and youth from a variety of cultural, racial, ethnic, and linguistic backgrounds.
- Open Access
- 1 July 2021
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (7) , e2114712
Prevalence of Headache Days and Disability 3 Years After Participation in the Childhood and Adolescent Migraine Prevention Medication Trial
Migraine is a common neurological disease that often begins in childhood and persists into adulthood.1-4 It is the second most disabling disease in the world, yet it is underrecognized, undertreated, and underappreciated.5-9 For people ages 15 to 49 years, migraine is the top cause of years lived with disability.10,11 Because there are few rigorous pediatric trials,12,13 clinical care for youth with migraine is primarily based on expert opinion and extrapolation of adult medication trial data.11,14,15 The dearth of evidence for pediatric patients motivated the Childhood and Adolescent Migraine Prevention (CHAMP) trial (NCT01581281),16 a multicenter study funded by the National Institutes of Health. The CHAMP trial compared the 2 most commonly used medications in current practice, amitriptyline17 and topiramate,12,18,19 with a placebo and with each other. The trial included youth ages 8 to 17 years with migraine (migraine without aura, migraine with aura, and chronic migraine) who reported between 4 and 28 headache days during the 28-day baseline and had at least mild levels of disability. The trial protocol, baseline data, and primary results have been published previously.14,16,20,21
- 1 July 2021
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (7) , e2114712
Open AccessPrevalence of Headache Days and Disability 3 Years After Participation in the Childhood and Adolescent Migraine Prevention Medication Trial
Migraine is a common neurological disease that often begins in childhood and persists into adulthood.1-4 It is the second most disabling disease in the world, yet it is underrecognized, undertreated, and underappreciated.5-9 For people ages 15 to 49 years, migraine is the top cause of years lived with disability.10,11 Because there are few rigorous pediatric trials,12,13 clinical care for youth with migraine is primarily based on expert opinion and extrapolation of adult medication trial data.11,14,15 The dearth of evidence for pediatric patients motivated the Childhood and Adolescent Migraine Prevention (CHAMP) trial (NCT01581281),16 a multicenter study funded by the National Institutes of Health. The CHAMP trial compared the 2 most commonly used medications in current practice, amitriptyline17 and topiramate,12,18,19 with a placebo and with each other. The trial included youth ages 8 to 17 years with migraine (migraine without aura, migraine with aura, and chronic migraine) who reported between 4 and 28 headache days during the 28-day baseline and had at least mild levels of disability. The trial protocol, baseline data, and primary results have been published previously.14,16,20,21
- 24 May 2021
- Published by Springer Nature in Journal of Clinical Psychology in Medical Settings
- Vol. 29 (1) , 113-119
Predictors of Improvement in Pediatric Chronic Migraine: Results from the Cognitive-Behavioral Therapy and Amitriptyline Trial
Explore predictors of improvement in headache days and migraine-related disability through a secondary analysis of the cognitive-behavioral therapy plus amitriptyline trial in children and adolescents (Clinical Trials Registration Number: NCT00389038). Participants were 135 youth aged 10–17 years old diagnosed with chronic migraine. Predictor variables included group assignment (treatment or control), baseline scores from depression and quality of life measures, and demographic variables. Criterion variables included headache days and migraine-related disability. Higher baseline depression scores were indicative of more days with headache post-treatment regardless of group assignment. Family income at the higher-end of the low-income range was significantly associated with less migraine-related disability regardless of group assignment (Household Income: HINC-01 in The United States Census Bureau. Bureau, U, 2020). Results from this secondary analysis identify depression symptoms and family income as predictors that can impact headache frequency and migraine-related disability. Self-reported symptoms of depression and family income are important factors to consider as part of the biopsychosocial model of care.
- 24 May 2021
- Published by Springer Nature in Journal of Clinical Psychology in Medical Settings
- Vol. 29 (1) , 113-119
Predictors of Improvement in Pediatric Chronic Migraine: Results from the Cognitive-Behavioral Therapy and Amitriptyline Trial
Explore predictors of improvement in headache days and migraine-related disability through a secondary analysis of the cognitive-behavioral therapy plus amitriptyline trial in children and adolescents (Clinical Trials Registration Number: NCT00389038). Participants were 135 youth aged 10–17 years old diagnosed with chronic migraine. Predictor variables included group assignment (treatment or control), baseline scores from depression and quality of life measures, and demographic variables. Criterion variables included headache days and migraine-related disability. Higher baseline depression scores were indicative of more days with headache post-treatment regardless of group assignment. Family income at the higher-end of the low-income range was significantly associated with less migraine-related disability regardless of group assignment (Household Income: HINC-01 in The United States Census Bureau. Bureau, U, 2020). Results from this secondary analysis identify depression symptoms and family income as predictors that can impact headache frequency and migraine-related disability. Self-reported symptoms of depression and family income are important factors to consider as part of the biopsychosocial model of care.
- 16 November 2018
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 59 (2) , 289-297
Cognitive Behavioral Therapy for Pediatric Headache and Migraine: Why to Prescribe and What New Research Is Critical for Advancing Integrated Biobehavioral Care
Purpose of Review: To highlight current evidence supporting the prescription of cognitive behavioral therapy (CBT) as part of first‐line preventive treatment for children and adolescents with headache and discuss a research strategy aimed at: (1) understanding how and why CBT works, and (2) developing effective and efficient approaches for integrating CBT into headache specialty, neurology, and primary care settings. Recent Findings: Although preventive medications for pediatric headache and migraine are commonly prescribed, recent meta‐analyses and an NIH‐funded, multi‐center clinical trial suggests that the effect of pill‐taking therapies may be mostly due to a placebo effect. These findings have led to greater consideration of prescription of non‐pharmacological therapies as first‐line interventions (either alone or in combination with pill‐based therapy). A literature that extends back to the 1980s and includes recent clinical trials and meta‐analyses demonstrates that CBT decreases headache frequency and related disability in youth with headache and migraine and has a favorable benefit to risk profile with almost no negative side effects. Summary: CBT has been repeatedly demonstrated as effective in treating pediatric headache and migraine. As such, it should be considered as part of first‐line preventive treatment for pediatric headache (either alone or in combination with a pill‐based therapy). We need to better understand how this therapy works and what makes it distinct (if anything) from the placebo effect. What we need to achieve is empirical support for efficient access to this evidence‐based treatment and clarity on how to match the intensity of non‐pharmacological intervention to the needs of our patients at the time they present for care.
- 16 November 2018
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 59 (2) , 289-297
Cognitive Behavioral Therapy for Pediatric Headache and Migraine: Why to Prescribe and What New Research Is Critical for Advancing Integrated Biobehavioral Care
Purpose of Review: To highlight current evidence supporting the prescription of cognitive behavioral therapy (CBT) as part of first‐line preventive treatment for children and adolescents with headache and discuss a research strategy aimed at: (1) understanding how and why CBT works, and (2) developing effective and efficient approaches for integrating CBT into headache specialty, neurology, and primary care settings. Recent Findings: Although preventive medications for pediatric headache and migraine are commonly prescribed, recent meta‐analyses and an NIH‐funded, multi‐center clinical trial suggests that the effect of pill‐taking therapies may be mostly due to a placebo effect. These findings have led to greater consideration of prescription of non‐pharmacological therapies as first‐line interventions (either alone or in combination with pill‐based therapy). A literature that extends back to the 1980s and includes recent clinical trials and meta‐analyses demonstrates that CBT decreases headache frequency and related disability in youth with headache and migraine and has a favorable benefit to risk profile with almost no negative side effects. Summary: CBT has been repeatedly demonstrated as effective in treating pediatric headache and migraine. As such, it should be considered as part of first‐line preventive treatment for pediatric headache (either alone or in combination with a pill‐based therapy). We need to better understand how this therapy works and what makes it distinct (if anything) from the placebo effect. What we need to achieve is empirical support for efficient access to this evidence‐based treatment and clarity on how to match the intensity of non‐pharmacological intervention to the needs of our patients at the time they present for care.
- Open Access
- 8 March 2018
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 58 (5) , 661-675
CBT for Pediatric Migraine: A Qualitative Study of Patient and Parent Experience
Objective: The goal of this study was to determine which cognitive behavioral therapy (CBT‐HA) treatment components pediatric headache patient stakeholders would report to be most helpful and essential to reducing headache frequency and related disability to develop a streamlined, less burdensome treatment package that would be more accessible to patients and families. Background: Pediatric migraine is a prevalent and disabling condition. CBT‐HA has been shown to reduce headache frequency and related disability, but may not be readily available or accepted by many migraine sufferers due to treatment burden entailed. Research is needed to determine systematic ways of reducing barriers to CBT‐HA. Methods: Qualitative interviews were conducted with 10 patients and 9 of their parents who had undergone CBT‐HA. Interviews were analyzed using an inductive thematic analysis approach based upon modified grounded theory. Patients were 13‐17.5 years of age ( M = 15.4, SD = 1.63) and had undergone CBT‐HA ∼1‐2 years prior to participating in the study. Results: Overall, patients and their parents reported that CBT‐HA was helpful in reducing headache frequency and related disability. Although patients provided mixed reports on the effectiveness of different CBT‐HA skills, the majority of patients indicated that the mind and body relaxation skills of CBT‐HA (deep breathing, progressive muscle relaxation, and activity pacing in particular) were the most helpful and most frequently used skills. Patients and parents also generally reported that treatment was easy to learn, and noted at least some aspect of treatment was enjoyable. Conclusions: Results from these qualitative interviews indicate that mind and body CBT‐HA relaxation skills emerged as popular and effective based on patient and parent report. Future research examining the effectiveness of streamlined pediatric migraine nonpharmacological interventions should include these patient‐preferred skills.
- 8 March 2018
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 58 (5) , 661-675
Open AccessCBT for Pediatric Migraine: A Qualitative Study of Patient and Parent Experience
Objective: The goal of this study was to determine which cognitive behavioral therapy (CBT‐HA) treatment components pediatric headache patient stakeholders would report to be most helpful and essential to reducing headache frequency and related disability to develop a streamlined, less burdensome treatment package that would be more accessible to patients and families. Background: Pediatric migraine is a prevalent and disabling condition. CBT‐HA has been shown to reduce headache frequency and related disability, but may not be readily available or accepted by many migraine sufferers due to treatment burden entailed. Research is needed to determine systematic ways of reducing barriers to CBT‐HA. Methods: Qualitative interviews were conducted with 10 patients and 9 of their parents who had undergone CBT‐HA. Interviews were analyzed using an inductive thematic analysis approach based upon modified grounded theory. Patients were 13‐17.5 years of age ( M = 15.4, SD = 1.63) and had undergone CBT‐HA ∼1‐2 years prior to participating in the study. Results: Overall, patients and their parents reported that CBT‐HA was helpful in reducing headache frequency and related disability. Although patients provided mixed reports on the effectiveness of different CBT‐HA skills, the majority of patients indicated that the mind and body relaxation skills of CBT‐HA (deep breathing, progressive muscle relaxation, and activity pacing in particular) were the most helpful and most frequently used skills. Patients and parents also generally reported that treatment was easy to learn, and noted at least some aspect of treatment was enjoyable. Conclusions: Results from these qualitative interviews indicate that mind and body CBT‐HA relaxation skills emerged as popular and effective based on patient and parent report. Future research examining the effectiveness of streamlined pediatric migraine nonpharmacological interventions should include these patient‐preferred skills.
- 1 December 2017
- Published by SAGE Publications in Clinical Practice in Pediatric Psychology
- Vol. 5 (4) , 404-414
Adolescent and Caregiver Perspectives on Provider–Patient Interactions in Type 2 Diabetes
This study aimed to describe the experience of adolescents with Type 2 diabetes and their caregivers during medical encounters, in an effort to improve clinical care and outcomes in this population. Twenty-eight families were recruited from a Midwestern diabetes clinic. Adolescents (13–18 years old) identified as Black (50%), Caucasian (43%), and Hispanic (7%), with variable levels of glycemic control (glycosylated hemoglobin A1c = 5.1–12.9%). Participants completed demographic and disease-related (adherence) questionnaires. Six adolescent and six caregiver focus groups were conducted and transcribed, coded, and systematically analyzed using principles of thematic analysis. Participants reported moderate to high rates of nonadherence. Qualitative themes indicated multiple factors influencing perceptions of the quality of provider–patient interactions. Participants’ experiences of these interactions was affected by provider characteristics (e.g., gender, age), provider approach and communication style, systemic issues (e.g., long wait times), and caregivers assuming primary roles in medical encounters (e.g., more caregiver participation and caregiver disclosure of nonadherence). Focus group discussions provided rich information about the experiences of adolescents with Type 2 diabetes and implicate barriers in provider–patient interactions, including challenges in triadic interactions and communication around nonadherence, suggesting these areas should be considered in efforts to improve provider–patient interactions within this population.
- 1 December 2017
- Published by SAGE Publications in Clinical Practice in Pediatric Psychology
- Vol. 5 (4) , 404-414
Adolescent and Caregiver Perspectives on Provider–Patient Interactions in Type 2 Diabetes
This study aimed to describe the experience of adolescents with Type 2 diabetes and their caregivers during medical encounters, in an effort to improve clinical care and outcomes in this population. Twenty-eight families were recruited from a Midwestern diabetes clinic. Adolescents (13–18 years old) identified as Black (50%), Caucasian (43%), and Hispanic (7%), with variable levels of glycemic control (glycosylated hemoglobin A1c = 5.1–12.9%). Participants completed demographic and disease-related (adherence) questionnaires. Six adolescent and six caregiver focus groups were conducted and transcribed, coded, and systematically analyzed using principles of thematic analysis. Participants reported moderate to high rates of nonadherence. Qualitative themes indicated multiple factors influencing perceptions of the quality of provider–patient interactions. Participants’ experiences of these interactions was affected by provider characteristics (e.g., gender, age), provider approach and communication style, systemic issues (e.g., long wait times), and caregivers assuming primary roles in medical encounters (e.g., more caregiver participation and caregiver disclosure of nonadherence). Focus group discussions provided rich information about the experiences of adolescents with Type 2 diabetes and implicate barriers in provider–patient interactions, including challenges in triadic interactions and communication around nonadherence, suggesting these areas should be considered in efforts to improve provider–patient interactions within this population.